IsoRay Company Profile (NYSEMKT:ISR)

About IsoRay (NYSEMKT:ISR)

IsoRay logoIsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:ISR
  • CUSIP: N/A
  • Web:
  • Market Cap: $27.51 million
  • Outstanding Shares: 55,017,000
Average Prices:
  • 50 Day Moving Avg: $0.54
  • 200 Day Moving Avg: $0.56
  • 52 Week Range: $0.48 - $0.71
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 8.33
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $4.45 million
  • Price / Sales: 6.18
  • Book Value: $0.22 per share
  • Price / Book: 2.27
  • EBITDA: ($5,880,000.00)
  • Net Margins: -135.40%
  • Return on Equity: -65.23%
  • Return on Assets: -56.78%
  • Average Volume: 92,378 shs.
  • Short Ratio: 20.54

Frequently Asked Questions for IsoRay (NYSEMKT:ISR)

What is IsoRay's stock symbol?

IsoRay trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "ISR."

How were IsoRay's earnings last quarter?

IsoRay, Inc. (NYSEMKT:ISR) announced its quarterly earnings data on Thursday, September, 28th. The company reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.02. The firm had revenue of $1.37 million for the quarter. IsoRay had a negative return on equity of 65.23% and a negative net margin of 135.40%. View IsoRay's Earnings History.

Where is IsoRay's stock going? Where will IsoRay's stock price be in 2017?

1 brokers have issued 1 year price objectives for IsoRay's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate IsoRay's share price to reach $3.00 in the next twelve months. View Analyst Ratings for IsoRay.

Who are some of IsoRay's key competitors?

Who are IsoRay's key executives?

IsoRay's management team includes the folowing people:

  • Thomas C. LaVoy, Chairman of the Board, Chief Executive Officer
  • Mark Austin, Principal Financial Officer, Principal Accounting Officer, Controller
  • William Cavanagh III, Chief Operating, Scientific Officer
  • Michael Krachon, Vice President of Sales and Marketing
  • Alan Hoffmann, Independent Director
  • Michael W. McCormick, Independent Director
  • Philip J. Vitale M.D., Independent Director

How do I buy IsoRay stock?

Shares of IsoRay can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IsoRay's stock price today?

One share of IsoRay stock can currently be purchased for approximately $0.50.

MarketBeat Community Rating for IsoRay (NYSEMKT ISR)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  72
MarketBeat's community ratings are surveys of what our community members think about IsoRay and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for IsoRay (NYSEMKT:ISR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00
Consensus Price Target History for IsoRay (NYSEMKT:ISR)
Price Target History for IsoRay (NYSEMKT:ISR)
Analysts' Ratings History for IsoRay (NYSEMKT:ISR)
DateFirmActionRatingPrice TargetDetails
9/28/2017Maxim GroupReiterated RatingBuy$3.00View Rating Details
(Data available from 10/20/2015 forward)


Earnings History for IsoRay (NYSEMKT:ISR)
Earnings by Quarter for IsoRay (NYSEMKT:ISR)
Earnings History by Quarter for IsoRay (NYSEMKT ISR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/28/2017Q4 2017($0.01)($0.03)$1.37 millionViewN/AView Earnings Details
5/10/2017Q3 2017($0.02)$1.28 millionViewN/AView Earnings Details
2/8/2017Q2 2017($0.03)$1.03 millionViewN/AView Earnings Details
11/9/2016Q1 2017($0.03)$1.08 millionViewN/AView Earnings Details
9/8/2016Q416($0.02)$1.12 millionViewN/AView Earnings Details
5/10/2016Q316($0.02)$1.16 million$1.20 millionViewN/AView Earnings Details
2/9/2016Q216($0.02)$1.07 million$1.19 millionViewN/AView Earnings Details
11/10/2015Q116($0.01)($0.02)$1.04 million$1.46 millionViewN/AView Earnings Details
9/15/2015Q4($0.01)($0.02)$1.34 millionViewN/AView Earnings Details
5/18/2015Q3($0.01)($0.02)$1.13 million$1.16 millionViewN/AView Earnings Details
2/18/2015Q215($0.02)($0.02)$1.07 millionViewN/AView Earnings Details
5/16/2014Q314($0.03)($0.05)$1.13 million$1.13 millionViewN/AView Earnings Details
11/14/2013Q1($0.06)$1.06 million$1.05 millionViewN/AView Earnings Details
5/15/2013Q313($0.03)($0.02)$1.12 million$1.25 millionViewN/AView Earnings Details
2/14/2013Q2 2013($0.03)($0.03)$1.32 million$0.95 millionViewN/AView Earnings Details
11/14/2012Q113($0.03)($0.03)$1.55 million$1.06 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IsoRay (NYSEMKT:ISR)
Current Year EPS Consensus Estimate: $0.01 EPS
Next Year EPS Consensus Estimate: $0.06 EPS


Dividend History for IsoRay (NYSEMKT:ISR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IsoRay (NYSEMKT:ISR)
Insider Trades by Quarter for IsoRay (NYSEMKT:ISR)
Insider Trades by Quarter for IsoRay (NYSEMKT:ISR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/10/2017Thomas C LavoyCEOBuy20,000$0.53$10,600.00View SEC Filing  
1/4/2017Philip J VitaleDirectorBuy20,000$0.66$13,200.00View SEC Filing  
12/8/2016Alan HoffmannDirectorBuy20,000$0.57$11,400.00View SEC Filing  
11/17/2016Thomas C LavoyCEOBuy20,000$0.60$12,000.00View SEC Filing  
3/17/2016Thomas C LavoyCEOBuy13,294$0.90$11,964.60View SEC Filing  
3/11/2016Philip J VitaleDirectorBuy10,000$0.93$9,300.00View SEC Filing  
3/11/2016Thomas C LavoyCEOBuy36,706$0.89$32,668.34View SEC Filing  
3/8/2016Michael W MccormickDirectorBuy22,000$0.87$19,140.00View SEC Filing  
11/12/2015Dwight William BabcockCEOBuy25,000$1.27$31,750.00View SEC Filing  
6/9/2015Dwight William BabcockCEOBuy10,000$1.53$15,300.00View SEC Filing  
3/6/2015Thomas C LavoyDirectorBuy10,000$1.66$16,600.00View SEC Filing  
3/5/2015Philip J VitaleDirectorBuy10,000$1.80$18,000.00View SEC Filing  
3/3/2015Dwight William BabcockCEOBuy10,029$1.51$15,143.79View SEC Filing  
11/1/2013Dwight William BabcockCEOBuy25,000$0.53$13,250.00View SEC Filing  
11/28/2012Thomas C LavoyDirectorBuy18,100$0.49$8,869.00View SEC Filing  
11/21/2012Dwight William BabcockCEOBuy10,100$0.40$4,040.00View SEC Filing  
11/19/2012Dwight William BabcockCEOBuy4,800$0.37$1,776.00View SEC Filing  
11/19/2012Robert R KauffmanDirectorBuy25,000$0.38$9,500.00View SEC Filing  
11/16/2012Dwight William BabcockCEOBuy35,100$0.42$14,742.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for IsoRay (NYSEMKT:ISR)
Latest Headlines for IsoRay (NYSEMKT:ISR)
DateHeadline logoEarnings Review and Free Research Report: AngioDynamics Reported Lower than Expected Quarterly Results - October 11 at 4:45 PM logoETFs with exposure to IsoRay, Inc. : October 10, 2017 - October 10 at 7:26 PM logoShould You Sell IsoRay Inc (ISR) For This Reason? - October 6 at 1:13 AM logoIsoRay, Inc. :ISR-US: Earnings Analysis: Q4, 2017 By the Numbers : October 4, 2017 - October 5 at 6:44 AM logoIsoRay, Inc. :ISR-US: Earnings Analysis: 2017 By the Numbers : October 2, 2017 - October 2 at 12:59 PM logoIsoRay's (ISR) "Buy" Rating Reiterated at Maxim Group - September 29 at 4:40 PM logoIsoRay, Inc. (ISR) Announces Earnings Results - September 29 at 8:06 AM logoIsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase - September 28 at 12:09 PM logoIsoRay reports 4Q loss - September 28 at 12:09 PM logoIsoRay Announces Study Accepted for Publication in the International Journal of Radiation Oncology, Biology, Physics entitled "Re-irradiation using Permanent Interstitial Brachytherapy (PIB): A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies" - September 26 at 10:18 AM logoIsoRay (ISR) Announces Poster Presentation at ASTRO Conf. - - September 25 at 9:32 AM logoIsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference - September 25 at 9:32 AM logoIsoRay (ISR) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 12 at 4:50 PM logoIs IsoRay Inc (ISR) Undervalued? - September 6 at 7:57 PM logoIsoRay Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017 - August 31 at 8:03 PM logoIsoRay, Inc. (ISR) Set to Announce Quarterly Earnings on Wednesday - August 30 at 1:38 AM logoIsoRay (ISR) Reports Prelim. Q4 Revenue of $1.37M - - August 5 at 6:51 PM logoIsoRay (ISR) Reports Prelim. Q4 Revenue of $1.37M - August 4 at 8:16 PM logoIsoRay Announces Preliminary Fourth Quarter F2017 Revenue of $1.37 Million, 22% Year-over-Year Increase - August 4 at 8:16 PM logoNew Study Shows Brachytherapy And Cesium-131 Isotope Treatment Beneficial For Prostate Cancer Patients - August 1 at 3:16 PM logoIsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer - July 8 at 11:53 AM logoIsoRay, Inc. (ISR) PT Set at $3.00 by Maxim Group - July 7 at 6:56 PM logoIsoRay Receives FDA Response to 510(k) Application for GammaTile™ - July 7 at 6:35 AM logoIsoRay (ISR) Reports Published Study on the Impact of Permanent Low-Dose Rate Cesium-131 Brachytherapy on ... - - June 22 at 1:01 PM logoIsoRay Gains on Positive Effect of Brachytherapy Treatment for Brain Cancer - June 20 at 6:55 PM logoForm 8-K IsoRay, Inc. For: May 10 - - May 10 at 11:17 PM logoIsoRay (ISR) Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology ... - - May 5 at 5:59 PM logoIsoRay (ISR) Announces Final Court Approval of Class Action Settlement - - March 10 at 7:13 PM logoISORAY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - March 10 at 7:13 PM logoIsoRay Announces Final Court Approval of Class Action Settlement - March 9 at 8:39 PM logo4:06 pm IsoRay announces that the previously announced Stipulation of Settlement has been approved by the U.S. District Court for the Eastern District of Washington - March 9 at 8:39 PM logoIsoRay Announces Second Quarter Fiscal 2017 Financial Results - PR Newswire (press release) - February 9 at 4:48 AM logoIsoRay Announces Second Quarter Fiscal 2017 Financial Results - February 8 at 6:45 PM logoISORAY, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers - January 23 at 6:17 PM logoIsoRay's chief financial officer resigns - January 20 at 12:50 AM logoPurcell Julie & Lefkowitz LLP Is Investigating IsoRay, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of ... - PR Newswire (press release) - January 11 at 6:36 PM



IsoRay (ISR) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.